TWI403333B - 含非類固醇系消炎鎮痛劑之外用經皮製劑 - Google Patents
含非類固醇系消炎鎮痛劑之外用經皮製劑 Download PDFInfo
- Publication number
- TWI403333B TWI403333B TW095106563A TW95106563A TWI403333B TW I403333 B TWI403333 B TW I403333B TW 095106563 A TW095106563 A TW 095106563A TW 95106563 A TW95106563 A TW 95106563A TW I403333 B TWI403333 B TW I403333B
- Authority
- TW
- Taiwan
- Prior art keywords
- weight
- parts
- acid
- agent
- transdermal preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 55
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title claims abstract description 10
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims description 64
- -1 benzidamin Chemical compound 0.000 claims description 59
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical group OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 40
- 230000000873 masking effect Effects 0.000 claims description 39
- 229960000991 ketoprofen Drugs 0.000 claims description 37
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 32
- 230000003637 steroidlike Effects 0.000 claims description 30
- 239000000730 antalgic agent Substances 0.000 claims description 21
- 239000011505 plaster Substances 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 12
- 230000000202 analgesic effect Effects 0.000 claims description 8
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- FPQRLYLHBYMKMK-UHFFFAOYSA-N 1-tert-butyl-4-[1-(4-methoxyphenyl)ethyl]benzene Chemical compound C1=CC(OC)=CC=C1C(C)C1=CC=C(C(C)(C)C)C=C1 FPQRLYLHBYMKMK-UHFFFAOYSA-N 0.000 claims description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 5
- 229960001680 ibuprofen Drugs 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 claims description 4
- 229960001671 azapropazone Drugs 0.000 claims description 4
- 229960003184 carprofen Drugs 0.000 claims description 4
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims description 4
- 229960002702 piroxicam Drugs 0.000 claims description 4
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 4
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 claims description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
- 229960005430 benoxaprofen Drugs 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 229960001259 diclofenac Drugs 0.000 claims description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 3
- 229960002009 naproxen Drugs 0.000 claims description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
- 229960001312 tiaprofenic acid Drugs 0.000 claims description 3
- 229960001017 tolmetin Drugs 0.000 claims description 3
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims 4
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims 1
- 239000001263 FEMA 3042 Substances 0.000 claims 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 229960001985 dextromethorphan Drugs 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 229960004492 suprofen Drugs 0.000 claims 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims 1
- 229940033123 tannic acid Drugs 0.000 claims 1
- 235000015523 tannic acid Nutrition 0.000 claims 1
- 229920002258 tannic acid Polymers 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 42
- 230000005764 inhibitory process Effects 0.000 abstract description 9
- 230000001900 immune effect Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 58
- 239000000203 mixture Substances 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 239000004615 ingredient Substances 0.000 description 18
- 239000006071 cream Substances 0.000 description 17
- 239000004744 fabric Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 14
- 230000008076 immune mechanism Effects 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000013508 migration Methods 0.000 description 12
- 230000005012 migration Effects 0.000 description 12
- 108091008695 photoreceptors Proteins 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000002674 ointment Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 230000007233 immunological mechanism Effects 0.000 description 9
- 229920000728 polyester Polymers 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 7
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229960001047 methyl salicylate Drugs 0.000 description 7
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 7
- 229960004889 salicylic acid Drugs 0.000 description 7
- 241000723346 Cinnamomum camphora Species 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 229960000846 camphor Drugs 0.000 description 6
- 229930008380 camphor Natural products 0.000 description 6
- 210000000624 ear auricle Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 229960002389 glycol salicylate Drugs 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 6
- 235000019477 peppermint oil Nutrition 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- KSEBMYQBYZTDHS-UHFFFAOYSA-N 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 4
- 229960003608 clomifene Drugs 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000005033 polyvinylidene chloride Substances 0.000 description 4
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- GUHQWKGQAYBNEW-UHFFFAOYSA-N 2-ethylhexyl propanoate Chemical compound CCCCC(CC)COC(=O)CC GUHQWKGQAYBNEW-UHFFFAOYSA-N 0.000 description 3
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- 231100000220 OECD 429 (LLNA) Skin Sensitisation Toxicity 0.000 description 3
- 206010034960 Photophobia Diseases 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000001361 adipic acid Substances 0.000 description 3
- 235000011037 adipic acid Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000005417 aminobenzoic acid derivatives Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 150000008366 benzophenones Chemical class 0.000 description 3
- 150000001565 benzotriazoles Chemical class 0.000 description 3
- 229940007061 capsicum extract Drugs 0.000 description 3
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 3
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 3
- 229960003338 crotamiton Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 3
- 229940100463 hexyl laurate Drugs 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 208000013469 light sensitivity Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 239000003883 ointment base Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 229960001173 oxybenzone Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229920006267 polyester film Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000002759 woven fabric Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- SQZBBBJJIMBYIW-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-4,4-dimethylpentane-1,3-dione Chemical compound COC1=CC=C(C(=O)CC(=O)C(C)(C)C)C=C1OC SQZBBBJJIMBYIW-UHFFFAOYSA-N 0.000 description 2
- BSZXAFXFTLXUFV-UHFFFAOYSA-N 1-phenylethylbenzene Chemical class C=1C=CC=CC=1C(C)C1=CC=CC=C1 BSZXAFXFTLXUFV-UHFFFAOYSA-N 0.000 description 2
- PITPRNOGWXAZAW-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-4-methoxyphenol Chemical compound COC1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 PITPRNOGWXAZAW-UHFFFAOYSA-N 0.000 description 2
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 2
- HFCUBKYHMMPGBY-UHFFFAOYSA-N 2-methoxyethyl prop-2-enoate Chemical compound COCCOC(=O)C=C HFCUBKYHMMPGBY-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEOKUACAYMUXCI-UHFFFAOYSA-N C(C(O)CO)(=O)O.C(C(C)O)O Chemical compound C(C(O)CO)(=O)O.C(C(C)O)O HEOKUACAYMUXCI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- UUGLJVMIFJNVFH-UHFFFAOYSA-N Hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1 UUGLJVMIFJNVFH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
- 229940043276 diisopropanolamine Drugs 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- FVDRFBGMOWJEOR-UHFFFAOYSA-N hexadecan-2-ol Chemical compound CCCCCCCCCCCCCCC(C)O FVDRFBGMOWJEOR-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000011419 induction treatment Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- OXGBCSQEKCRCHN-UHFFFAOYSA-N octadecan-2-ol Chemical compound CCCCCCCCCCCCCCCCC(C)O OXGBCSQEKCRCHN-UHFFFAOYSA-N 0.000 description 2
- YBGZDTIWKVFICR-UHFFFAOYSA-N octinoxate Chemical compound CCCCC(CC)COC(=O)C=CC1=CC=C(OC)C=C1 YBGZDTIWKVFICR-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000001782 photodegradation Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- QYUGGQFEZYGJPG-UHFFFAOYSA-N (2-tert-butylphenyl)methanol Chemical compound CC(C)(C)C1=CC=CC=C1CO QYUGGQFEZYGJPG-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- MWSZIMKFELTDLK-UHFFFAOYSA-N 16-methylheptadecyl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound COC1=CC(C=CC(=O)OCCCCCCCCCCCCCCCC(C)C)=CC=C1O MWSZIMKFELTDLK-UHFFFAOYSA-N 0.000 description 1
- KNENSDLFTGIERH-UHFFFAOYSA-N 2,2,4,4-tetramethyl-3-phenylpentan-3-ol Chemical compound CC(C)(C)C(O)(C(C)(C)C)C1=CC=CC=C1 KNENSDLFTGIERH-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- BVCOHOSEBKQIQD-UHFFFAOYSA-N 2-tert-butyl-6-methoxyphenol Chemical compound COC1=CC=CC(C(C)(C)C)=C1O BVCOHOSEBKQIQD-UHFFFAOYSA-N 0.000 description 1
- PSJBSUHYCGQTHZ-UHFFFAOYSA-N 3-Methoxy-1,2-propanediol Chemical compound COCC(O)CO PSJBSUHYCGQTHZ-UHFFFAOYSA-N 0.000 description 1
- HORVLKADAZQYRS-UHFFFAOYSA-N 4,4-dimethyl-1-phenylpentane-1,3-dione Chemical class CC(C)(C)C(=O)CC(=O)C1=CC=CC=C1 HORVLKADAZQYRS-UHFFFAOYSA-N 0.000 description 1
- XIOBZUDJYKXUEL-UHFFFAOYSA-N 4-ethyl-2-[(4-methoxyphenyl)methylidene]octanoic acid Chemical compound CCCCC(CC)CC(C(O)=O)=CC1=CC=C(OC)C=C1 XIOBZUDJYKXUEL-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical group NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- ODVQQGJJRAIWMW-UHFFFAOYSA-N C(CCCCC)OC(C1C(C=CC=C1)=CC1=C(C=C(C=C1)N(CC)CC)O)=O Chemical compound C(CCCCC)OC(C1C(C=CC=C1)=CC1=C(C=C(C=C1)N(CC)CC)O)=O ODVQQGJJRAIWMW-UHFFFAOYSA-N 0.000 description 1
- QUVCFQAHXXKABX-UHFFFAOYSA-K C(CO)(=O)[O-].O[Al+]O Chemical compound C(CO)(=O)[O-].O[Al+]O QUVCFQAHXXKABX-UHFFFAOYSA-K 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229960003140 clofezone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- PDQKLEYJZYUZCZ-UHFFFAOYSA-N diphenylmethanone methane Chemical group C.C=1C=CC=CC=1C(=O)C1=CC=CC=C1 PDQKLEYJZYUZCZ-UHFFFAOYSA-N 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- VUPKGFBOKBGHFZ-UHFFFAOYSA-N dipropyl carbonate Chemical compound CCCOC(=O)OCCC VUPKGFBOKBGHFZ-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- HEAHZSUCFKFERC-UHFFFAOYSA-N ecamsule Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC(C=C1)=CC=C1C=C1C(=O)C2(CS(O)(=O)=O)CCC1C2(C)C HEAHZSUCFKFERC-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950003801 epirizole Drugs 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- HBPVKGYQTMAQDM-UHFFFAOYSA-N ethene;2-hydroxybenzoic acid Chemical compound C=C.OC(=O)C1=CC=CC=C1O HBPVKGYQTMAQDM-UHFFFAOYSA-N 0.000 description 1
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- QAKXLTNAJLFSQC-UHFFFAOYSA-N hexadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC QAKXLTNAJLFSQC-UHFFFAOYSA-N 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940023607 myristic acid Drugs 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- YDLYQMBWCWFRAI-UHFFFAOYSA-N n-Hexatriacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC YDLYQMBWCWFRAI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- IEDOGKKOPNRRKW-UHFFFAOYSA-N octadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC IEDOGKKOPNRRKW-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229940032159 propylene carbonate Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229920006132 styrene block copolymer Polymers 0.000 description 1
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- LGWZGBCKVDSYPH-UHFFFAOYSA-N triacontane Chemical compound [CH2]CCCCCCCCCCCCCCCCCCCCCCCCCCCCC LGWZGBCKVDSYPH-UHFFFAOYSA-N 0.000 description 1
- OLTHARGIAFTREU-UHFFFAOYSA-N triacontane Natural products CCCCCCCCCCCCCCCCCCCCC(C)CCCCCCCC OLTHARGIAFTREU-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- GAAKLDANOSASAM-UHFFFAOYSA-N undec-10-enoic acid;zinc Chemical compound [Zn].OC(=O)CCCCCCCCC=C GAAKLDANOSASAM-UHFFFAOYSA-N 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 229940098697 zinc laurate Drugs 0.000 description 1
- 229940105125 zinc myristate Drugs 0.000 description 1
- 229940012185 zinc palmitate Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
- 229940118257 zinc undecylenate Drugs 0.000 description 1
- GPYYEEJOMCKTPR-UHFFFAOYSA-L zinc;dodecanoate Chemical compound [Zn+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O GPYYEEJOMCKTPR-UHFFFAOYSA-L 0.000 description 1
- GJAPSKMAVXDBIU-UHFFFAOYSA-L zinc;hexadecanoate Chemical compound [Zn+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O GJAPSKMAVXDBIU-UHFFFAOYSA-L 0.000 description 1
- GBFLQPIIIRJQLU-UHFFFAOYSA-L zinc;tetradecanoate Chemical compound [Zn+2].CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O GBFLQPIIIRJQLU-UHFFFAOYSA-L 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/445—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本發明為關於一種含有非類固醇系消炎鎮痛劑之外用經皮製劑。
酮洛芬(Ketoprofen)等非類固醇系消炎鎮痛劑,因為具有優良之抗炎作用及鎮痛作用,常含於濕布劑或硬附劑等貼附劑、膠劑、乳膏劑、軟膏劑、抹劑等各種形態之外用經皮製劑中作為藥效成分。但非類固醇系消炎鎮痛劑之外用經皮製劑為光感受性者,雖然極少發生,但曾有報告其在過度曝光時具有經由非免疫性或免疫性的機制表現皮膚症狀的可能性。
為嘗試抑制源自光感受性藥劑之症狀,已往之報告如在含酮洛芬之外用製劑中調配紫外線吸收劑,以防止酮洛芬之光分解,抑制光分解物生成之例(參考專利文獻1);及對含非類固醇系消炎鎮痛劑之貼附劑之支持體施以紫外線遮蔽加工之例(參考專利文獻2);及在抗炎症皮膚外用劑中調配氧化鈦之例(參考專利文獻3);因此期待能改善製劑使其更能防止皮膚症狀。
專利文獻1:日本專利特開昭60-155111號公報
專利文獻2:國際公開第01/68061號公報
專利文獻3:日本專利特開平9-169658號公報
專利文獻4:日本專利特開昭53-99316號公報
專利文獻5:日本專利特開昭56-22711號公報
專利文獻6:日本專利特開2000-136122號公報
非專利文獻1:日本皮膚科學會雜誌,113(4),405-411(2003)
非專利文獻2:Photochemistry and photobiology,73(2),119-27(2001)
本發明之目的在提供一種含有光感受性之非類固醇系消炎鎮痛劑之外用經皮製劑,在受光照射時可確實防止源自此藥劑之皮膚症狀。
本發明人等為解決上述課題而刻意檢討,源自光感受性藥劑之皮膚症狀係由於藥劑受日光照射時所產生的活性氧,對組織‧細胞造成傷害,為非免疫性機制所產生者,同時對過度日光曝露而半抗源(hapten)化之藥劑,經由免疫性機制於組織‧細胞造成障礙者;前者與個體因素無關,具有因接受大量紫外光照射而產生症狀之可能性,相對之下,後者雖係由於半抗原化藥劑之免疫性敏感作用,而僅在部份個體產生症狀,然而一旦於敏感作用時,具有無法使用該藥劑之可能性,因此要確實防止該皮膚症狀,須要由抑制兩方機制著手。
源自光感受性藥劑之皮膚症狀,已知是因為紫外光中,特別是長波長紫外光(UVA:波長320nm至400nm)所引發(參考例如非專利文獻1及2),因此有各種試驗在製劑中調配各種UVA遮蔽劑,但並非所有UVA遮蔽劑均可有效防止前述皮膚症狀,其中並有相反地使症狀更惡化者存
在。因此又再進一步研究,結果意外發現,包含UVA遮蔽劑及UVB遮蔽劑之UV遮蔽劑中,具有良好的皮膚遷移性者,對於咸信為構成前述皮膚症狀之非免疫性症狀及免疫性症狀兩者的抑制,特別有效,而完成本發明。UV遮蔽劑之皮膚遷移性與前述皮膚症狀之抑制之關聯性尚為至今為所未知,因此本發明之此種效果為超出熟悉此項技術領域者所預想者。
亦即,本發明係關於含有光感受性非類固醇系消炎鎮痛劑,及皮膚遷移性高之UV遮蔽劑之外用經皮製劑。
本發明亦為關於上述外用經皮製劑,其中之非類固醇系消炎鎮痛劑為由酮洛芬(ketoprofen)、替阿洛芬酸(tiaprofenic acid)、斯洛芬(suprofen)、脫美汀(tolmetin)、卡洛芬(carprofen)、苯諾塞洛芬(benoxaprofen)、皮洛昔康(piroxicam)、苯古達明(benzidamin)、納洛辛(naproxen)、二氯芬酸(diclofenac)、依布洛芬(ibuprofen)、二氟尼塞(difulnisal)、阿札丙宗(azapropazone)及其藥理上容許之鹽所成組群中選擇者。
本發明亦為關於上述外用經皮製劑,其中之UV遮蔽劑為由二苯甲醯基甲烷衍生物、二苯甲酮(benzophenone)衍生物、肉桂酸衍生物、樟腦衍生物、苯并***衍生物、胺基酸衍生物、苯甲醯基頻那酮(benzoyl pinacolone)衍生物及胺基苯甲酸衍生物所成組群中選擇者。
本發明亦為關於上述外用經皮製劑,其中之UV遮蔽劑
為由4-第三丁基-4’-甲氧基二苯甲醯基甲烷、2-(4-二乙基胺基-2-羥基苯甲醯基)苯甲酸-正己酯、4-羥基-3-甲氧基肉桂酸、4-羥基-3-甲氧基肉桂酸之支鏈烷基酯、亞對酞基-3,3’-二樟腦基-10,10’-二磺酸((terephthalylidene dicamphor sulfonic acid),此處之“亞對酞基”即指“對苯二亞甲基”)、2-(2H-苯并***-2-基)-4-甲基-6-[2-甲基-3-[1,3,3,3-四甲基-1[(三甲基矽烷基)氧基]二矽氧烷基]丙基]酚、二甲氧基苯亞甲基二側氧基咪唑啶丙酸-2-乙基己基酯、1-(3,4-二甲氧基苯基)-4,4-二甲基-1,3-戊二酮、2-(2’-羥基-5’-甲氧基苯基)-苯并***、羥苯甲酮(oxybenzone)(亦即2-羥基-4-甲氧基二苯甲酮)、4-胺基苯甲酸乙酯、4-甲氧基肉桂酸-2-乙基己酯所成組群中選擇者。
本發明之外用經皮製劑,可明顯抑制光感受性非類固醇系消炎鎮痛劑產生之光誘導性之症狀。即本發明中由皮膚遷移性高之UV遮蔽劑,有效抑制前述皮膚症狀的原因之源自光感受性藥劑中活性氧及自由基的產生,及該藥劑的半抗原化等。
本發明之外用經皮製劑相關之抑制皮膚症狀之機制仍未甚明,惟咸信是因為UV遮蔽劑與光感受性非類固醇系消炎鎮痛劑一起於皮膚遷移,不只於製劑中亦包括於皮膚中抑制該消炎鎮痛劑的光化學反應等,而為有效抑制上述症狀者。
目前雖已知有調配紫外線吸收劑之外用劑(參考專利
文獻1、3至6),但其目的均為減低製劑中紫外線之不良影響(參考專利文獻1、3至5)、及防止日曬(參考專利文獻6)者,並無任何著眼於UV遮蔽劑之皮膚遷移性的例子。例如在專利文獻6中揭示之皮膚外用劑雖含對甲氧基肉桂酸-2-乙基己酯等紫外線控制劑、引朵美辛(indomethacin)等抗炎症劑、及金屬螯合劑,並非含有如本發明中所載之光感受性非類固醇系消炎鎮痛劑之例,發明的效果而言,亦僅止於檢討曝露於紫外線所引起之紅斑及色素沉積等非免疫學之皮膚症狀,完全未提及免疫學方面之皮膚症狀,因此,並無任何關於源自光感受性消炎鎮痛劑之免疫學機制中存在之皮膚症狀本身及如何抑制。因此,本發明為首先實現以調配皮膚遷移性高之UV遮蔽劑而防止源自光感受性非類固醇系消炎鎮痛劑之皮膚症狀之外用經皮製劑。
本發明之外用經皮製劑,對非免疫學或免疫學的機制所產生之源自光感受性藥劑之皮膚症狀的表現充分防止,且可使消炎鎮痛效果奏效,為期待作為安全性極高之醫藥品的應用。
以下即對本發明之外用經皮製劑之較佳實施方式詳細說明。
本發明之外用經皮製劑之特徵為含有光感受性之非類固醇系消炎鎮痛劑以及皮膚遷移性高之UV遮蔽劑。
本發明之外用經皮製劑中所使用之UV遮蔽劑以皮膚遷移性高者為佳,在皮膚特別是角質層中保留性高者更
佳。因此,本發明製劑中使用之UV遮蔽劑以具此等特性之二苯甲醯基甲烷衍生物、二苯甲酮衍生物、肉桂酸衍生物、樟腦衍生物、苯并***衍生物、胺基酸衍生物、苯甲醯基頻那酮衍生物、胺基苯甲酸衍生物等有機系UV遮蔽劑為佳。本發明之外用經皮製劑,二苯甲醯基甲烷衍生物以4-第三丁基-4’-甲氧基二苯甲醯基甲烷,二苯甲酮衍生物以2-(4-二乙基胺基-2-羥基苯甲醯基)苯甲酸-正己酯及二苯甲酮,肉桂酸衍生物或其酯以4-羥基-3-甲氧基肉桂酸、4-羥基-3-甲氧基肉桂酸異硬脂酯等4-羥基-3-甲氧基肉桂酸之支鏈烷基酯、及4-甲氧基肉桂酸-2-乙基己酯,樟腦衍生物以亞對酞基-3,3’-二樟腦基-10,10’-二磺酸,苯并***衍生物以2-(2H-苯并***-2-基)-4-甲基-6-[2-甲基-3-[1,3,3,3-四甲基-1[(三甲基矽烷基)氧基]二矽氧烷基]丙基]酚及2-(2’-羥基-5’-甲氧基苯基)-苯并***,胺基酸系化合物以二甲氧基苯亞甲基二側氧基咪唑啶丙酸-2-乙基己基酯,苯甲醯基頻那醇衍生物以1-(3,4-二甲氧基苯基)-4,4-二甲基-1,3-戊二酮,胺基苯甲酸衍生物以4-胺基苯甲酸乙酯為佳。
本發明之外用經皮製劑中所使用之UV遮蔽劑特別以4-第三丁基-4’-甲氧基二苯甲醯基甲烷較佳。
UV遮蔽劑之皮膚遷移量(保留量)可以例如由無毛鼠(hairless mice)等採取之皮膚切片,在以生理食鹽水等生理溶液濕潤之濾紙上展開,在該皮膚切片使用試驗物質經預定之時間,例如4至8小時,典型為6小時左右放置後,
以該試驗物質使用部份為中心切下皮膚切片的預定面積,去除該皮膚表面的殘餘試驗物質,定量皮膚中試驗物質質量。
本發明之外用經皮製劑中,上述UV遮蔽劑之配合量並無特別之限定,但以製劑總量為基準之0.01至20重量%為佳,1至10重量%更佳,又特別以2至5重量%更佳。UV遮蔽劑之配合量在前述下限以上時可有效地抑制前述皮膚症狀,另一方面在前述上限以下時可避免意料外之反應。其中所稱之「抑制」之意,指其中所含之UV遮蔽劑,在以耳垂照光試驗(參考試驗例1)等評估之非免疫性機制皮膚症狀相關之數據,及以局部淋巴結試驗(參考試驗例2及4)、皮膚光敏感試驗(參考試驗例3)等評估之免疫性機制皮膚症狀相關之數據,比未含上述UV遮蔽劑時為少。其減少之程度(抑制率)以4%以上為佳,30%以上更佳,50%以上又更佳,60%以上最佳。
本發明如前述為一種含有光感受性非類固醇系消炎鎮痛劑作為藥效成分之外用經皮製劑,可確實防止非免疫性機制或免疫性機制所產生之皮膚症狀。此等非類固醇系消炎鎮痛劑,只要為具光感受性者,更典型者為光照時具產生上述皮膚症狀之可能性者,其他並無特別之限制,其例如酮洛芬、替阿洛芬酸、斯洛芬、氟必洛芬(flurbiprofen)、羅索洛芬(loxoprofen)、脫美汀、卡洛芬、苯諾塞洛芬、皮洛昔康、苯吉達明、納洛辛、二氯芬酸、依布洛芬、二氟尼塞、阿札丙宗、水楊酸甲酯、乙二
醇水楊酸酯、伐地克昔(valdecoxib)、希里克昔(celecoxib)、羅非克昔(rofecoxib)、乙醯基胺基苯(acetaminophen)、甲滅酸(mefenamic acid)、氯非宗(clofezone)、斯爾比林(sulpyrine)、阿明洛芬(alminoprofen)、納洛辛、普拉洛芬(pranoprofen)、甲匹啶佐(mepirizole)、丙(oxaprozin)、替諾昔康(tenoxicam)、氯諾昔康(lornoxicam)、美洛昔康(meloxicam)及/或其等之藥理上容許之鹽,其中以具有類似苯醯苯骨架之酮洛芬、替阿洛芬酸、斯洛芬、脫美汀為佳,且以具有類似二苯甲酮(benzophenone)骨架之酮洛芬更佳。此等非類固醇系消炎鎮痛劑可以單獨使用,亦可以其2種以上適當組合使用。
本發明之外用經皮製劑中,上述非類固醇系消炎鎮痛劑之配合量並無特別之限制,以製劑總量為基準之0.1至10重量%為佳。非類固醇系消炎鎮痛劑之配合量在前述下限以上時,可有優良之消炎鎮痛效果。
UV遮蔽劑與非類固醇系消炎鎮痛劑之較佳組合並無特別之限定,可例如以4-第三丁基-4’-甲氧基二苯甲醯基甲烷、2-(2’-羥基-5’-甲氧基苯基)-苯并***、亞對酞基-3,3’-二樟腦基-10,10’-二磺酸、羥苯甲酮、4-胺基苯甲酸乙酯及4-甲氧基肉桂酸-2-乙基己酯之群中選擇1種或2種以上之UV遮蔽劑與酮洛芬組合。其中4-第三丁基-4’-甲氧基二苯甲醯基甲烷、亞對酞基-3,3’-二樟腦基-10,10’-二磺酸、羥苯甲酮及4-胺基苯甲酸乙酯之群中選
擇1種或2種以上之UV遮蔽劑與酮洛芬之組合較佳,特別以4-第三丁基-4’-甲氧基二苯甲醯基甲烷與酮洛芬之組合更佳。另一方面,專利文獻6中揭示之2,2’,4,4’-四羥基二苯甲酮、4-胺基苯甲酸及乙二醇單水楊酸酯可能使上述皮膚症狀更差,因此本發明中與酮洛芬組合不佳。
本發明之外用經皮製劑中,可以依各製劑之劑型在上述必須成分(前述本發明相關之非類固醇系消炎鎮痛劑、UV遮蔽劑)之外,再含各製劑之基劑。本發明之外用經皮製劑之劑型可舉如濕布劑或硬膏劑等貼附劑、膠劑、乳膏劑、軟膏劑、抹劑等,其中以非類固醇系消炎鎮痛劑之吸收性較佳之貼附劑,在發揮本發明優良效果之觀點方面較佳。以下即以本發明之外用經皮製劑之各種劑型之基劑及處方例說明。
首先說明濕布劑。本發明之濕布劑中使用之濕布基劑並無特別之限定,可以由一般使用者中選擇。此種濕布基劑中所含之成分可舉如增黏劑(聚丙烯酸鈉、聚丙烯酸、聚乙烯醇、聚乙烯吡咯烷酮、聚環氧乙烷、聚甲基丙烯酸乙烯酯等合成水溶性高分子,***膠、澱粉、明膠等天然物,甲基纖維素、羥丙基纖維素、精胺酸、精胺酸鈉、精胺酸銨、羧甲基纖維素鈉等),濕潤劑(尿素、甘油、聚乙二醇、丙二醇、丁二醇、山梨糖醇等),填充劑(高嶺土、滑石、皂土、環氧樹脂類,有機酸(檸檬酸、酒石酸、順丁烯二酸、順丁烯二酸酐、琥珀酸等),鈣、鎂、鋁等)、水、助溶劑(碳酸丙烯酯、克羅米通(crotamiton)、己二酸二異
丙酯等),皮膚炎症防止劑(鹽酸苯海拉明(difenhydramin)、順丁烯二酸氯非尼拉明(chlorpheniramine)、甘草酸、***(dexamethasone)、貝他米松(betamethasone)、醋酸氟輕松(fluocinolone acetonide)等),及其他之添加劑(水楊酸、水楊酸甲酯、水楊酸二醇、1-薄荷醇、樟腦、正壬基莢蘭酚醯酸胺、辣椒萃取物、薄荷油、艾依宗(音譯;註冊商標)等)等,混合此等中選擇之各成份製成之濕布基劑再配合前述之必須成分,即可製成本發明之濕布劑。
其次再舉濕布劑之較佳製造例(處方例)。先將0.1至10重量份之前述非類固醇系消炎鎮痛劑、0.01至20重量份之前述UV遮蔽劑與0.5至8重量份之助溶劑混合使其溶解成均勻之混合物A。另一方面,將5至20重量份(10至15重量份更佳)之增黏劑與5至40重量份之濕潤劑及10至80重量份之水混合分散使其溶解,再加入20重量份以下之填充劑製成均勻之混拌物B。其次,在混合物A中加入混拌物B,製成均勻之混拌物。該製成之混拌物再依一般之方法在載持體上展開塗布後,再於其上貼附剝離被覆物即製成本發明之濕布劑。載持體可使用伸縮性或非伸縮性之載持體。該載持體之具體例可舉如布、不織布、聚胺酯、聚酯、聚乙酸乙烯酯、聚偏二氯乙烯、聚乙烯、聚苯二甲酸乙烯酯、鋁箔或此等之複合素材製成之物等。剝離被覆物之例可舉如聚乙烯、聚丙烯、聚氯乙烯、聚酯、聚偏二氯乙烯、矽膠加工紙製成之物等。
其次再說明硬膏劑。本發明之硬膏劑中使用之硬膏基劑並無特別之限定,可以由一般使用者中選擇。此等硬膏基劑中所含之成分可舉如高分子基劑(與甲基丙烯酸酯類、丙烯腈、乙酸乙烯酯、丙酸乙烯酯等乙烯系單體之共聚物之丙烯酸系組成物、矽膠樹脂、聚異戊二烯橡膠、天然橡膠、丙烯酸系橡膠、苯乙烯-丁二烯-苯乙烯嵌段共聚物、苯乙烯-異戍二烯-苯乙烯嵌段共聚物等)、油脂或高級脂酸(核桃油、橄欖油、茶油、杏仁油、花生油、甘油三油酸酯、液體石蠟、聚丁烯等)、黏結劑(松脂、松脂改質順丁烯二酸、氫化松脂等)、脂肪酸金屬鹽(十一碳烯酸鋅、硬脂酸鋅、硬脂酸鈣、硬脂酸鋁、硬脂酸鎂、硬脂酸鈉、棕櫚酸鋅、肉豆蔻酸鋅、肉豆蔻酸鎂、月桂酸鈉、月桂酸鋅等)、皮膚炎症防止劑、其他之添加物(水楊酸、水楊酸甲酯、水楊酸乙二醇酯、1-薄荷醇、樟腦、正壬基莢蘭酚醯酸胺、辣椒萃取物、薄荷油、艾依宗等)等,混合此等中選擇之各成份製成硬膏基劑,再配合前述之必須成分,即可製成本發明之硬膏劑。
其次再舉硬膏劑之較佳製造例(處方例)。首先,以熱熔法製造時,先在120至160℃使用揑和機、攪拌機等混合機將5至40重量份之前述高分子基劑、20至70重量份之前述油脂或高級脂肪酸、10至40重量份之前述黏結劑及0.1至10重量份之前述脂肪酸金屬鹽加熱混合,其次再加入0.1至10重量份之前述非類固醇系消炎鎮痛劑、0.01至20重量份之前述UV遮蔽劑加以混合。該製成之混合物
再直接於載持體上展開,或於經離型處理之紙、膜等上先展開後,再加壓轉覆於所要使用之載持體成覆蓋狀態。另外,以溶劑法製造時,先以防爆型攪拌機等混合機使前述成分溶解於甲苯、己烷、二氯甲烷等溶劑中,再將該溶液在經離型處理之紙、膜等上展開,再經乾燥機蒸餾去除溶劑後,再加壓轉覆於所要使用之載持體成覆蓋狀態。再將其展開塗布於載持體上使其貼附於剝離被覆物,製成本發明之硬膏劑。該載持體之具體例可舉如布、不織布、聚胺酯、聚酯、聚乙酸乙烯酯、聚偏二氯乙烯、聚乙烯、聚苯二甲酸乙烯酯、鋁箔或此等之複合素材製成之物等。剝離被覆物之例可舉如聚乙烯、聚丙烯、聚氯乙烯、聚酯、聚偏二氯乙烯、矽膠加工紙製成之物等。
其次再說明軟膏劑。本發明之軟膏劑中使用之軟膏基劑並無特別之限定,可以由一般使用之物中選擇。此種軟膏基劑中所含之成分可舉如高級脂肪酸或此等之酯類(已二酸、肉豆蔻酸、棕櫚酸、硬脂酸、油酸、已二酸酯、肉豆蔻酸酯、棕櫚酸酯、癸二酸二乙酯、月桂酸己酯、異辛酸十六烷酯等)、蠟類(鯨蠟、蜜蠟、純地蠟等)、界面活性劑(聚氧伸乙基烷基醚磷酸酯等)、高級醇(十六烷醇、硬脂醇、十六碳硬脂醇(cetostearyl alcohol)等)、矽油(二甲基聚矽氧烷、甲基苯基聚矽氧烷、二醇甲基聚矽氧烷、矽油二醇聚合物等)、烴類(親水性凡士林、白凡士林、精製棉羊油、液體石蠟等)、水、吸收促進劑(碳酸伸丙二酯、己二酸二異丙酯、克羅米通、艾依宗等)、保濕劑(甘油、
丙二醇、丁二醇、山梨糖醇等),皮膚炎症防止劑,及其他之添加劑(水楊酸、水楊酸甲酯、水楊酸乙二醇酯、1-薄荷醇、樟腦、薄荷油等)等,混合此等中選擇之各成份製成之軟膏基劑,再配合前述之必須成分,即可製成本發明之軟膏劑。
其次再舉軟膏劑之較佳製造例(處方例)。先在室溫或加熱下將5至15重量份之高級脂肪酸酯、1至10重量份之界面活性劑及0.1至10重量份之前述非類固醇系消炎鎮痛劑、0.01至20重量份之前述UV遮蔽劑混合,再加入4至10重量份之蠟類、50至90重量份之烴類並加熱,保持於50至100℃下。在全部成分形成透明溶解溶液後,再以均質攪拌機混合均勻。之後,再一面攪拌該製成之混合物一面使其降溫至室溫,即製成本發明之軟膏劑。
其次再說明膠劑。本發明之膠劑中使用之膠基劑並無特別之限定,可以由一般使用者中選擇。此種膠基劑中所含之成分可舉如低級醇(乙醇、異丙醇等)、水、膠體化劑(羧乙烯聚合體、羥乙基纖維素、羥丙基纖維素、甲基纖維素、乙基纖維素、羧甲基纖維素、精胺酸丙二醇酯等)、中和劑(三乙醇胺、二異丙醇胺、氫氧化鈉等)、界面活性劑(倍半油酸山梨糖醇酐酯、三油酸山梨糖醇酐酯、單油酸山梨糖醇酐酯、單硬脂酸山梨糖醇酐酯、單月桂酸山梨糖醇酐酯、單硬脂酸聚乙二醇酯、聚氧伸乙基壬基苯基醚、聚氧伸乙基十六碳烷基醚、聚氧伸乙基月桂基醚等)、吸收促進劑(碳酸伸丙酯、癸二酸二乙酯、己二異丙酯、克羅米通、艾依
宗、丙二醇等)、助溶劑(乙醇、異丙醇等低級醇、十六碳烷醇、硬脂醇、二十二碳烷醇、油醇、十六碳烷醇、十八碳烷醇等高級醇,肉豆蔻酸異丙酯、肉豆蔻酸十八碳烷酯、肉豆蔻酸十六碳烷酯、肉豆蔻酸肉豆蔻酯、癸二酸二乙酯、癸二酸二異丙酯、已二酸二異丙酯、油酸油酯、月桂酸己酯、異辛酸十六碳烷酯,中鏈脂肪酸三甘油醇酯、丙二醇脂酸酯肪等脂肪酸酯,N-甲基-2-吡咯烷酮、三乙酸甘油酯、苯甲醇、羊毛醇、1-甲基縮甘油醚等)、二醇類(甘油醇、丙二醇、聚乙二醇、聚丙二醇、山梨糖醇、1,3-丁二醇、二丙二醇等)、皮膚炎症防止劑、及其他之添加劑(水楊酸、水楊酸甲酯、水楊酸乙二醇酯、1-薄荷醇、樟腦、薄荷油等)等,混合此等中選擇之各成份製成之膠基劑再配合前述之必須成分,即可製成本發明之膠劑。
其次再舉膠劑之較佳製造例(處方例)。先在55重量份以下之水中加入0.5至5重量份之膠體化劑,使其膨潤成膨潤物A。另一方面,在0.1至10重量份之前述非類固醇系消炎鎮痛劑、0.01至20重量份之前述UV遮蔽劑中加入0.1至10重量份之助溶劑使其溶解或懸浮,再加入40重量份以下之二醇類與60重量份以下之低級醇之混合物溶解,製成溶解物B。其次再將該溶解物B加入膨潤物A中,再加入中和劑調整其pH為4至7,即製成本發明之膠劑。
其次再說明乳膏劑。本發明之乳膏劑中使用之乳膏基劑並無特別之限定,可以由一般使用之物中選擇。此種乳膏基劑中所含之成分可舉如高級脂肪酸酯類(已二酸酯、肉
豆蔻酸酯、棕櫚酸酯、癸二酸二乙酯、月桂酸己酯、異辛酸十六烷酯等)、低級醇(乙醇、異丙醇等)、烴類(液體石蠟、三十碳烷等)、多元醇(丙二醇、1,3-丁二醇等)、高級醇類(2-十六碳烷醇、十六烷醇、2-十八碳烷醇等)、乳化劑(聚氧伸乙基烷基醚類、脂肪酸酯類、聚乙二醇脂酸酯等)、防腐劑(對羥基苯甲酸酯等)、吸收助劑(碳酸伸丙二酯、癸二酸二乙酯、己二酸二異丙酯、克羅米通、艾依宗、丙二醇等)、皮膚炎症防止劑及其他之添加劑(水楊酸、水楊酸甲酯、水楊酸乙二醇酯、1-薄荷醇、樟腦、薄荷油等)等,混合此等中選擇之各成份製成之乳膏基劑再配合前述之必須成分,即可製成本發明之乳膏劑。此外,製成具有乳膏劑與膠劑中間性質之膠狀乳膏劑時,可在上述乳膏劑中加入膠化劑(羧乙烯聚合物、羥乙基纖維素、羥丙基纖維素、甲基纖維素、乙基纖維素、羧甲基纖維素、精胺酸丙二醇酯等)、及中和劑(三乙醇胺、二異丙醇胺、氫氧化鈉等),再調整其pH為4至8(5至6.5更佳),即製成本發明之膠狀乳膏劑。
其次再舉乳膏劑之較佳製造例(處方例)。先將0.1至10重量份之前述非類固醇系消炎鎮痛劑、0.01至20重量份之前述UV遮蔽劑加入25重量份以下之高級脂酸酯及40重量份以下之低級醇之混合物中溶解,再加入0.5重量份以下之防腐劑、5重量份以下之乳化劑,製成混合物A。另一方面,在水中加入膠體化劑使其膨潤成濃度0.5至5重量份之膨潤物B。其次再將該膨潤物B加入混合物A中,
再以均質攪拌機乳化均勻後,再於該製成之乳化物中加入中和劑調整其pH為4至8,即製成本發明之膠狀乳膏劑。
其次再說明抹劑。本發明之抹劑中使用之抹劑基劑並無特別之限定,可以由一般使用者中選擇。此種抹劑基劑中所含之成分可舉如混合10至70重量份之醇類(乙醇、丙醇、異丙醇等1價醇,聚乙二醇、丙二醇、丁二醇等多元醇等)、60重量份以下之脂肪酸酯(已二酸、癸二酸、肉豆蔻酸之各種酯等)、10重量份以下之界面活性劑(聚氧伸乙基烷基醚、聚氧伸乙基硬化蓖麻油等)之物,再於此抹劑基劑中調配0.1至10重量份之前述非類固醇系消炎鎮痛劑、0.01至20重量份之前述UV遮蔽劑,即可製成本發明之抹劑。本發明之抹劑中在必要時亦可再加入中和劑調整其pH,或甲基纖維素等增黏劑、皮膚炎症防止劑、及其他之添加劑(水楊酸、水楊酸甲酯、水楊酸乙二醇酯、1-薄荷醇、樟腦、薄荷油、辣椒萃取物、正壬基莢蘭酚醯酸胺、克羅米通、艾依宗、碳酸伸丙二酯、己二酸二異丙酯等)等。
上述之處方例及製造法為單一之例,當然可以以一般已知之抹劑製造法製成本專利申請發明中之抹劑。配合之組成中,亦可將一般已知之抹劑中之藥效成分取代為酮洛芬等,再配合UV遮蔽劑,即可簡單地製成本專利申請發明中之抹劑。
以上之說明為依本發明之外用經皮製劑中之各種劑型,以適當之基劑及處方例之實施形態加以說明,但其劑型及處方例並不限定於此,各成分之配合順序亦無特別之
限定。例如在一般已知之點眼劑之處方或一般已知之噴霧劑之處方中,其藥效成分可取代為0.1至10重量份之前述之非類固醇系消炎鎮痛劑,之後再調配0.01至20重量份之前述之UV遮蔽劑,即可製成本發明之點眼劑或噴霧劑。
本發明之外用經皮製劑在上述處方中亦可再配合抗氧化劑。此等抗氧化劑以第三丁基羥基苯甲醚、二-第三丁基羥基甲苯、麝香草酚、沒食子酸丙酯等酚衍生物、生育醇及其酯衍生物、抗壞血酸或其酯衍生物等較佳。此等抗氧化劑可單獨1種或以其2種以上組合使用。其配合量並無特別之限定,但以製劑總量為基準之0至10重量%為佳,0至5重量%更佳。
以下即以實施例更具體說明本發明,但本發明並不限定於此等實施例。實施例中之「%」在未特別限定下即指「重量%」。
以下之實驗係參考Gerberick人等之方法(Food Chem.,Toxicolo.,27,813-819(1989))或改良其部份。其中之試驗動物使用Balb/c小鼠(雌性,9至11週齡),在其耳垂上塗布以乙醇溶解試驗物質製成之{4-第三丁基-4’-甲氧基二苯甲醯基甲烷(BM-DBM)、二甲氧基苯亞甲基二側氧基咪唑啶丙酸-2-乙基己基酯(DB-DIH)、亞對酞基-3,3’-二樟腦基-10,10’-二磺酸(TP-DCS)、2-(4-二乙基胺基-2-羥基苯甲醯基)苯甲酸正己酯(DHB-BH)}或2%酮洛芬(KP)後,再
以40 J/cm2之UVA照射。之後測定照射UVA 24小時後之耳厚,計算試驗開始前增加之耳厚之比例。各試驗物質抑制照光時KP所引發之非免疫性機制之皮膚症狀之效果,是以抑制KP所造成耳厚增加比例之程度為指標,即相對KP組之耳浮腫之抑制率(%)評估。其所得之結果如表1及表2所示。
由表1及表2所示之結果可知,在含有作為藥效成分之酮洛芬之外用經皮製劑中調配皮膚遷移性高之UV遮蔽劑時,可明顯減少其照光時之非免疫性機制之皮膚症狀。
本實驗中使用The Interagency Coordinating Committee on the Validation of Alternative Methods
(ICCVAM)中所舉之Murine Local Lymph Node Assay(LLNA)之改良方法,測定照光時KP引發之免疫性機制之皮膚症狀。其中之試驗動物使用Balb/c小鼠(雌性,8至12週齡),在其耳翼背部上塗布以丙酮-橄欖油(4:1,v/v)溶解製成之試驗物質{4-第三丁基-4’-甲氧基二苯甲醯基甲烷(BM-DBM)}及2%之酮洛芬(KP)後,再以20 J/cm2之UVA照射。以該處理連續操作3日。在開始誘發敏感5日後,再自其尾部以每隻小鼠20μCi之3H-甲基胸腺嘧啶(3H-TdR)/PBS溶液靜脈注射,在5小時後取出其淋巴結。該取出之淋巴結再以細胞培養篩(cell strainer)懸浮成單一淋巴細胞懸浮液後,再以PBS洗淨2次後,在4℃下在5%三氯乙酸(TCA)溶液中靜置一晚,使其中之DNA沉澱。其沉澱物再懸浮於1mL% 5%TCA溶液中之後,再以液體閃爍計數器測定其中之放射線活性。上述試驗物質對KP由來之皮膚症狀之抑制效果,是以KP可以抑制3H-TdR增加進入之程度為指標,即相對KP組之3H-TdR進入之抑制率(%)評估。其所得之結果如表3所示。
由表3之結果可知,在含有作為藥效成分之酮洛芬之外用經皮製劑中調配皮膚遷移性高之UV遮蔽劑時,可明顯減少其照光時之免疫性機制之皮膚症狀。
UV遮蔽劑對照光時KP所引發之免疫性機制之皮膚症狀及其影響,是以天竺鼠之Adjuvant Strip法(佐藤等,西日本皮膚科,42,831-837(1980))之改良方法進行檢討。使用哈德雷系白色天竺鼠(1組8隻),除去其頸背部毛後,取2×2cm大小之部位在4角投予佐劑,再以乙醇溶解之2%酮洛芬(KP)或2% KP+2%試驗物{4-第三丁基-4’-甲氧基二苯甲醯基甲烷(BM-DBM)}溶液開放塗布於2×2cm部位,經1小時後再照射UVA(10 J/cm2)。該敏感誘導處理經連續操作5日。於敏感開始後3週時,去除其腰背部毛,以與敏感時相同之溶液開放塗布於2×2cm部位,經1小時後再照射UVA(10 J/cm2)誘發光敏感。再依上述佐藤等之基準分別評估24、48小時後之皮膚反應。BM-DBM對光照射時之KP誘發免疫性機制之皮膚症狀之抑制效果,是以相對KP組之紅腫及浮腫抑制率(%)評估。其所得之結果如表4所示。
由表4之結果可知,在含有作為藥效成分之酮洛芬之外用經皮製劑中調配皮膚遷移性高之UV遮蔽劑時,可明顯減少其照光時之免疫性機制之皮膚症狀。
本實驗是以上述LLNA以外之方法測定光照射下KP誘發免疫性機制之皮膚症狀。試驗動物使用Balb/c小鼠(雌性,8至12週齡),在其耳翼背部上塗布以丙酮-橄欖油(4:1,v/v)或丙酮-橄欖油-生理食鹽水(3:1:1,v/v)溶解製成濃度2%之試驗物質及濃度2%之KP後,再以20J/cm2之UVA照射。該敏感誘導處理連續操作3日。在敏感開始5日後,再自小鼠耳垂取出淋巴結,放置於PBS中使PBS充分附著於取出之淋巴結上,再測定其重量。試驗物質對免疫性機制之皮膚症狀之抑制效果,是以抑制該症狀導致之耳垂淋巴結重量增加比例(%)評估。其所得之結果如下所示。
由表5之結果可知,在含有作為藥效成分之酮洛芬之外用經皮製劑中調配皮膚運送性高之UV遮蔽劑時,可明顯減少其照光時之免疫性機制之皮膚症狀。
其次揭示本發明之外用經皮製劑之處方例,惟本發明並不以下列處方為限。
將16重量份之苯乙烯-異戊二烯-苯乙烯嵌段共聚體(SIS5200P:JSR Micro,Inc製造)、10重量份之聚異丁烯(L-100:Exxon Mobil Co.製造)、19重量份之石油樹脂(Alcon P-70:荒川化學工業公司製造)、45重量份之液體石蠟(Krystol J-352:ESSO石油公司製造)及1.99重量份之合成矽酸鋁於氮氣環境下加熱攪拌以得到溶解物(步驟
A)。攪拌時之溫度為110至200℃,攪拌時間為30至120分鐘。其次再於上述溶解物之攪拌溫度在110至200℃範圍內將3重量份之克羅米通、0.01重量份之4-第三丁基-4’-甲氧基二苯甲醯基甲烷、2重量份之%酮洛芬、及3重量份之1-薄荷醇加入,攪拌5至30分鐘成混合均勻之溶解物,即製成硬膏劑用基劑(步驟B)。該基劑之重量為70cm2為1g,再於矽膠處理之聚酯膜上伸展開後,將其加壓轉覆於聚酯織布上,裁成所要之大小後,即製成本發明之硬膏劑。
以如表6所示之成分及配合量如處方例1調製,即製成本發明之硬膏劑。
將50重量份之丙烯酸-2-乙基己酯、25重量份之丙烯酸甲氧基乙酯、14.7重量份之乙酸乙烯酯、0.3重量份之氮雜貳異丁腈、3重量份之合成矽酸鋁、及100重量份之乙酸乙酯放於反應容器中,再於氮氣環境下升溫至65℃開始聚合,經反應10小時後,再於80℃下熟成2小時,即製成共聚物溶液。再於該製成之共聚物溶液中加入5重量份之4-第三丁基-4’-甲氧基二苯甲醯基甲烷、2重量份之酮洛芬混合成均勻之溶液,即製成硬膏劑用基劑。該基劑以重量每70cm2為1g的方式,再於矽膠處理之聚酯膜上伸展開,以熱風吹去其中之乙酸乙酯後,將其加壓轉覆於經矽油處理之聚酯織布,裁成所要之大小後,即製成本發明之硬膏劑。
將45重量份之丙烯酸-2-乙基己酯、25重量份之丙烯酸甲氧基乙酯、12重量份之乙烯吡咯烷酮、1重量份之苯甲醯過氧化物、3重量份之合成矽酸鋁、5重量份之4-第三丁基-4’-甲氧基二苯甲醯基甲烷、5重量份之2-第三丁基羥基甲苯、及100重量份之乙酸乙酯放於反應容器中,再於氮氣環境下升溫至65℃開始聚合,經反應10小時後,再於80℃下熟成2小時,即製成共聚物溶液。再於該製成之共聚物溶液中加入4重量份之酮洛芬混合成均勻之溶液,即製成硬膏劑用基劑。該基劑以重量每70cm2為1g的方式,於矽膠處理之聚酯膜上伸展開,以熱風吹去其
中之乙酸乙酯後,將其加壓轉覆於聚酯織布,裁成所要之大小後,即製成本發明之硬膏劑。
將0.3重量份之酮洛芬、及1重量份之4-第三丁基-4’-甲氧基二苯甲醯基甲烷、0.5重量份之克羅米通混合成均勻之溶液,即製成混合物A。另一方面,將6重量份之聚丙烯酸鈉、3重量份之聚丙烯酸、2重量份之明膠、及1重量份之聚乙烯醇混合分散溶於20重量份之甘油、5重量份之山梨糖醇、及59.6重量份之水中,再加入0.5重量份之合成肉桂酸鋁、0.1重量份之胺基乙酸二羥基鋁、0.3重量份之矽酸鋁酸鎂、及0.2重量份之酒石酸混合均勻成混拌物B。其次將該混合物A加入混拌物B中,混合均勻後即製成混拌物。該製成之混拌物再於聚酯不織布上塗布展開後,再於其上貼附聚丙烯膜,即製成本發明之濕布劑。
以如表7所示之成分及配合量如處方例16調製,即製成本發明之濕布劑。
在4.7重量份之癸二酸二乙酯、及4.4重量份之甘由醇單油酸酯中加入2重量份之酮洛芬及0.4重量份之4-第三丁基-4’-甲氧基二苯甲醯基甲烷,於室溫或加熱下混合,再於其中加入6.8重量份之蜜蠟、8.1重量份之液體
石蠟、及73.6重量份之白凡士林後加熱,並保持於50至100℃下。至全部成分溶解成透明液體後,再經均質攪拌機混合。之後將該製成之混合物一面攪拌一面降溫至室溫,即製成本發明之軟膏劑。
以如表8所示之成分及配合量如處方例20調製,即製成本發明之軟膏劑。
在30.2重量份之精製水中加入1.8重量份之羧乙烯聚合物使其膨潤後,製成膨潤物A。另一方面,將3重量份
之替阿洛芬酸、2.5重量份之4-羥基-3-甲氧基肉桂酸異硬脂酯、及0.5重量份之二丁基羥基甲苯溶於13.7重量份之丙二醇與42.5重量份之無水乙醇之混合物中使其溶解,製成溶解物B。其次,將該溶解物B加入膨潤物A中之後,再加入0.9重量份之三乙醇胺,調整其pH後即製成本發明之膠劑。
以如表9所示之成分及配合量如處方例26調製,即製成本發明之膠劑。
以如表10所示之成分及配合量混合,即製成本發明之乳膏劑。
以如表11所示之成分及配合量混合,即製成本發明之抹劑。
如上所示,依據本發明所製成之含光感受性非類固醇系消炎鎮痛劑之外用經皮製劑,不只可確實防止照光時該成分所引發之非免疫性機制之皮膚症狀或免疫性機制之皮膚症狀,且可發揮其消炎鎮痛效果,因此可成為一種安全性極高之醫藥品。
Claims (4)
- 一種外用經皮製劑,其係含有光感受性之非類固醇系消炎鎮痛劑及由4-第三丁基-4’-甲氧基二苯甲醯基甲烷、亞對酞基-3,3’-二樟腦基-10,10’-二磺酸及4-胺基苯甲酸乙酯所成組群中選出之UV遮蔽劑之外用經皮製劑,UV遮蔽劑之配合量以製劑總量為基準之0.01至20重量%,其中該外用經皮製劑為不含有金屬螫合劑及麴酸與其衍生物之貼附劑。
- 如申請專利範圍第1項之外用經皮製劑,其中,該非類固醇系消炎鎮痛劑為自酮洛芬(ketoprofen)、替阿洛芬酸(tiaprofenic acid)、斯洛芬(suprofen)、脫美汀(tolmetin)、卡洛芬(carprofen)、苯諾塞洛芬(benoxaprofen)、皮洛昔康(piroxicam)、苯吉達明(benzidamin)、納洛辛(naproxen)、二氯芬酸(diclofenac)、依布洛芬(ibuprofen)、二氟尼塞(difulnisal)、阿札丙宗(azapropazone)及其等之藥理上容許之鹽所成組群中選出者。
- 一種外用經皮製劑,其係含有光感受性之非類固醇系消炎鎮痛劑及由4-第三丁基-4’-甲氧基二苯甲醯基甲烷、亞對酞基-3,3’-二樟腦基-10,10’-二磺酸及4-胺基苯甲酸乙酯所成組群中選出之UV遮蔽劑之外用經皮製劑,其中該外用經皮製劑為不含有金屬螫合劑及麴酸與其衍生物之硬膏劑。
- 如申請專利範圍第3項之外用經皮製劑,其中,該非類 固醇系消炎鎮痛劑為自酮洛芬(ketoprofen)、替阿洛芬酸(tiaprofenic acid)、斯洛芬(suprofen)、脫美汀(tolmetin)、卡洛芬(carprofen)、苯諾塞洛芬(benoxaprofen)、皮洛昔康(piroxicam)、苯吉達明(benzidamin)、納洛辛(naproxen)、二氯芬酸(diclofenac)、依布洛芬(ibuprofen)、二氟尼塞(difulnisal)、阿札丙宗(azapropazone)及其等之藥理上容許之鹽所成組群中選出者。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005050991 | 2005-02-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200640491A TW200640491A (en) | 2006-12-01 |
TWI403333B true TWI403333B (zh) | 2013-08-01 |
Family
ID=36927466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095106563A TWI403333B (zh) | 2005-02-25 | 2006-02-24 | 含非類固醇系消炎鎮痛劑之外用經皮製劑 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20080317689A1 (zh) |
EP (1) | EP1872796B1 (zh) |
JP (1) | JP5075622B2 (zh) |
KR (1) | KR101298183B1 (zh) |
CY (1) | CY1112111T1 (zh) |
DK (1) | DK1872796T3 (zh) |
ES (1) | ES2370511T3 (zh) |
HK (1) | HK1112719A1 (zh) |
PL (1) | PL1872796T3 (zh) |
PT (1) | PT1872796E (zh) |
SI (1) | SI1872796T1 (zh) |
TW (1) | TWI403333B (zh) |
WO (1) | WO2006090833A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5374365B2 (ja) * | 2007-04-23 | 2013-12-25 | 久光製薬株式会社 | 貼付剤 |
CN103974700B (zh) * | 2011-12-07 | 2015-12-09 | 久光制药株式会社 | 贴附剂 |
US8822537B2 (en) * | 2012-09-27 | 2014-09-02 | Achelios Therapeutics, Inc. | Topical ketoprofen composition |
EP2968652B1 (en) | 2013-03-13 | 2020-07-22 | Avery Dennison Corporation | Improving adhesive properties |
WO2015129808A1 (ja) | 2014-02-27 | 2015-09-03 | 久光製薬株式会社 | ケトプロフェン含有パップ剤 |
JP2023513668A (ja) | 2020-02-05 | 2023-04-03 | マレル・サーモン・アクティエセルスカブ | 箱からストラップを取り外すための装置、システム、および方法 |
CN113524933B (zh) * | 2021-08-09 | 2023-05-30 | 湖北金德包装有限公司 | 一种改性醇酸树脂的制备方法及其在油墨中的应用 |
CN113652117B (zh) * | 2021-09-07 | 2022-12-13 | 廊坊市安鼎新材料科技有限公司 | 一种环保油墨及其在印刷工艺方法中的应用 |
CN115322099B (zh) * | 2022-07-27 | 2024-04-02 | 五邑大学 | 萘普生-肉桂酸衍生物及其在制备治疗lps诱导炎症的药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60155111A (ja) * | 1983-10-20 | 1985-08-15 | Hisamitsu Pharmaceut Co Inc | 安定なケトプロフェン含有外用経皮製剤 |
US5637293A (en) * | 1993-10-28 | 1997-06-10 | Sansho Seiyaku Co., Ltd. | Preparation for epidermis |
JP2000136122A (ja) * | 1998-10-28 | 2000-05-16 | Kose Corp | 皮膚外用剤 |
TWI337086B (en) * | 2003-09-03 | 2011-02-11 | Hisamitsu Pharmaceutical Co | Transdermal formulation containing nonsteroidal antiinflammatory drug |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2544180C2 (de) * | 1975-10-03 | 1984-02-23 | Merck Patent Gmbh, 6100 Darmstadt | Lichtschutzmittel für kosmetische Zwecke |
JPS5399316A (en) | 1977-02-04 | 1978-08-30 | Sanpo Seiyaku Kk | Stbilyzing method of leserpine preparation |
JPS5622711A (en) | 1979-08-01 | 1981-03-03 | Pola Chem Ind Inc | Cosmetic prevented from photooxidizing |
DE69228313T2 (de) * | 1991-08-30 | 1999-09-23 | Hisamitsu Pharmaceutical Co | Entzündungshemmendes, analgetisches pflaster |
DE69535737T2 (de) * | 1994-09-16 | 2009-04-09 | Hisamitsu Pharmaceutical Co., Inc., Tosu-shi | Pflaster zur externen anwendung |
JPH09169658A (ja) | 1995-12-19 | 1997-06-30 | Pola Chem Ind Inc | 抗炎症皮膚外用剤 |
KR20010013377A (ko) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | 마일드한 잔류성 항균 조성물 |
US5989528A (en) * | 1998-07-30 | 1999-11-23 | The Procter & Gamble Company | Sunscreen compositions |
US6967023B1 (en) * | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
EP1269999B1 (en) * | 2000-03-17 | 2013-05-01 | Hisamitsu Pharmaceutical Co. Inc. | Ultraviolet-shielding patch |
FR2818127B1 (fr) * | 2000-12-18 | 2004-03-12 | Oreal | Composition filtrante photostable contenant un filtre du type derive du dibenzoylmethane et un compose 4,4-diarylbutadiene |
TWI327074B (en) * | 2003-05-07 | 2010-07-11 | Hisamitsu Pharmaceutical Co | Ultra violet shielding patch |
GB0322342D0 (en) * | 2003-09-23 | 2003-10-22 | Gamble Reed | Skin patch |
TWI341736B (en) * | 2003-12-26 | 2011-05-11 | Hisamitsu Pharmaceutical Co | Anti-infammatory adhesive preparations |
US7013835B2 (en) * | 2004-04-27 | 2006-03-21 | David Brokaski | Cat litter device |
TWI414320B (zh) * | 2004-05-13 | 2013-11-11 | Hisamitsu Pharmaceutical Co | 含有非類固醇系消炎鎮痛劑之外用經皮製劑 |
EP1767218B1 (en) * | 2004-06-15 | 2016-08-10 | Hisamitsu Pharmaceutical Co., Inc. | Antiinflammatory and analgesic preparation for external use |
-
2006
- 2006-02-24 DK DK06714545.8T patent/DK1872796T3/da active
- 2006-02-24 EP EP06714545A patent/EP1872796B1/en active Active
- 2006-02-24 SI SI200631165T patent/SI1872796T1/sl unknown
- 2006-02-24 TW TW095106563A patent/TWI403333B/zh active
- 2006-02-24 JP JP2007504809A patent/JP5075622B2/ja active Active
- 2006-02-24 ES ES06714545T patent/ES2370511T3/es active Active
- 2006-02-24 PT PT06714545T patent/PT1872796E/pt unknown
- 2006-02-24 KR KR1020077020791A patent/KR101298183B1/ko active IP Right Grant
- 2006-02-24 WO PCT/JP2006/303406 patent/WO2006090833A1/ja active Application Filing
- 2006-02-24 US US11/884,990 patent/US20080317689A1/en not_active Abandoned
- 2006-02-24 PL PL06714545T patent/PL1872796T3/pl unknown
-
2008
- 2008-02-15 HK HK08101695.8A patent/HK1112719A1/xx unknown
-
2010
- 2010-04-29 US US12/769,870 patent/US20100311700A1/en not_active Abandoned
-
2011
- 2011-12-02 CY CY20111101190T patent/CY1112111T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60155111A (ja) * | 1983-10-20 | 1985-08-15 | Hisamitsu Pharmaceut Co Inc | 安定なケトプロフェン含有外用経皮製剤 |
US5637293A (en) * | 1993-10-28 | 1997-06-10 | Sansho Seiyaku Co., Ltd. | Preparation for epidermis |
JP2000136122A (ja) * | 1998-10-28 | 2000-05-16 | Kose Corp | 皮膚外用剤 |
TWI337086B (en) * | 2003-09-03 | 2011-02-11 | Hisamitsu Pharmaceutical Co | Transdermal formulation containing nonsteroidal antiinflammatory drug |
Also Published As
Publication number | Publication date |
---|---|
EP1872796A1 (en) | 2008-01-02 |
KR20070104933A (ko) | 2007-10-29 |
KR101298183B1 (ko) | 2013-08-20 |
TW200640491A (en) | 2006-12-01 |
US20100311700A1 (en) | 2010-12-09 |
JP5075622B2 (ja) | 2012-11-21 |
CY1112111T1 (el) | 2015-11-04 |
DK1872796T3 (da) | 2011-10-17 |
PL1872796T3 (pl) | 2012-01-31 |
ES2370511T3 (es) | 2011-12-19 |
SI1872796T1 (sl) | 2011-12-30 |
US20080317689A1 (en) | 2008-12-25 |
EP1872796B1 (en) | 2011-09-21 |
PT1872796E (pt) | 2011-11-03 |
EP1872796A4 (en) | 2009-08-26 |
WO2006090833A1 (ja) | 2006-08-31 |
JPWO2006090833A1 (ja) | 2008-07-24 |
HK1112719A1 (en) | 2008-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI403333B (zh) | 含非類固醇系消炎鎮痛劑之外用經皮製劑 | |
JP5551630B2 (ja) | 非ステロイド系消炎鎮痛剤を含有する外用経皮製剤 | |
EP1558225A1 (en) | Adhesive composition for dermal patch and production process thereof | |
EP1752164B1 (en) | Percutaneous pharmaceutical preparation for external use containing nonsteroidal antiinflammatory analgesic | |
TW200520793A (en) | Anti-infammatory adhesive preparations | |
TWI294286B (en) | Stabilised topical formulations containing ketoprofen | |
RU2340335C2 (ru) | Стабилизированные композиции для местного применения, содержащие кетопрофен | |
EP1627644A1 (en) | PREPARTAION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND INTERLEUKIN-1a PRODUC TION INHIBITOR | |
JPH09169658A (ja) | 抗炎症皮膚外用剤 | |
JPS59170011A (ja) | 日焼け防止化粧料 | |
WO2013040447A2 (en) | Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis | |
KR101177826B1 (ko) | 비스테로이드계 소염 진통제를 함유하는 외용 경피 제제 | |
EP1703892A2 (de) | Uv-licht stabile halbfeste transdermale systeme, die einen lichtempfindlichen wirkstoff und einen uv-absorber enthalten |